Description
SWOT ANALYSIS OF NICORETTE
Nicorette
Parent Company
Licensee: GSK in US/ J&J in India
Category
Healthcare
Sector
FMCG
Doubles Your Chances of Quitting Smoking; For every cigarette there is Tagline/ Slogan a nicorette
It offers a pain-less way of quitting smoking by reducing the nicotine USP craving.
STP
Segment
OTC medicine
Target Group
People who want to quit smoking
A therapeutic nicotine-based gum which reduces the craving for Positioning nicotine among smokers
SWOT Analysis
1. Very well accepted in the global markets, available in more than 80 countries 2. Both GSK and J&J have a strong presence in pharmaceutical products with world class R&D and product innovation, the brand benefits from that. 3. A wide range of products available: three flavours - Original, Mint and Orange in different pack sizes to address needs of different consumers 4. Nicorette was the first medicinal preparation to facilitate smoking cessation and created a new category referred to as Nicotine Strength replacement therapy
1. Late entry in emerging economies 2. The brand has to work a lot in spreading awareness especially in the Weakness rural markets where reach of TV media is limited.
1. There are millions tobacco users & they smoke and use tobacco in Opportunity other forms like chewing tobacco. This large size of cigarette users also results in large number of health issues and in turn large number of
people who want to quit smoking. 2. The de marketing of cigarettes by government and NGOs also increase the number of wannabe quitters.
1. Pharma products are subject to stringent legal regulations; any mistake in adherence to quality etc can have strong implications 2. The acceptance of product in Indian markets would depend on cultural and social norms also. In some regions, smoking is a part of Threats the culture itself and people might not readily accept the product.
Competition
1. Nicoderm Competitors 2. Niconovum
doc_390699354.docx
SWOT ANALYSIS OF NICORETTE
Nicorette
Parent Company
Licensee: GSK in US/ J&J in India
Category
Healthcare
Sector
FMCG
Doubles Your Chances of Quitting Smoking; For every cigarette there is Tagline/ Slogan a nicorette
It offers a pain-less way of quitting smoking by reducing the nicotine USP craving.
STP
Segment
OTC medicine
Target Group
People who want to quit smoking
A therapeutic nicotine-based gum which reduces the craving for Positioning nicotine among smokers
SWOT Analysis
1. Very well accepted in the global markets, available in more than 80 countries 2. Both GSK and J&J have a strong presence in pharmaceutical products with world class R&D and product innovation, the brand benefits from that. 3. A wide range of products available: three flavours - Original, Mint and Orange in different pack sizes to address needs of different consumers 4. Nicorette was the first medicinal preparation to facilitate smoking cessation and created a new category referred to as Nicotine Strength replacement therapy
1. Late entry in emerging economies 2. The brand has to work a lot in spreading awareness especially in the Weakness rural markets where reach of TV media is limited.
1. There are millions tobacco users & they smoke and use tobacco in Opportunity other forms like chewing tobacco. This large size of cigarette users also results in large number of health issues and in turn large number of
people who want to quit smoking. 2. The de marketing of cigarettes by government and NGOs also increase the number of wannabe quitters.
1. Pharma products are subject to stringent legal regulations; any mistake in adherence to quality etc can have strong implications 2. The acceptance of product in Indian markets would depend on cultural and social norms also. In some regions, smoking is a part of Threats the culture itself and people might not readily accept the product.
Competition
1. Nicoderm Competitors 2. Niconovum
doc_390699354.docx